Yazar "Cimentepe, E." seçeneğine göre listele
Listeleniyor 1 - 5 / 5
Sayfa Başına Sonuç
Sıralama seçenekleri
Öğe ADAM9, ADAM10 and ADAM17 differentially regulated in male infertility(Wiley-Blackwell, 2016) Guven, K. N.; Bayram, N. A.; Pekel, A.; Yildirim, M. E.; Duvan, C. Iltemir; Cimentepe, E.; Onaran, Y.[Abstract Not Available]Öğe Protective Effect of Intravesical Platelet-Rich Plasma on Cyclophosphamide-Induced Hemorrhagic Cystitis(Canadian Soc Clinical Investigation, 2016) Ozyuvali, E.; Yildirim, M. E.; Yaman, T.; Kosem, B.; Cimentepe, E.Purpose: Hemorrhagic cystitis (HC) is the most common urotoxic side effect of cyclophosphamide (CYP). Platelet rich plasma (PRP) plays an important role in wound healing and inflammatory responses. The aim of this study was to investigate the efficacy of intravesical PRP at treatment of interstitial cystitis (IC). Methods: Female rats (n=24) were used. IC was induced by intraperitoneal injection of cyclophosphamide (CYP) and rats were randomly allocated to one of four groups (n = 6 per group): A control group; a sham group with saline (75 mg/kg; i.p.) instead of CYP on day 1, IC group, which was injected with CYP (150 mg/kg; i.p.) on day 1; and, an intravesical PRP-treated group which was injected with CYP (150 mg/kg; i.p.) on day 1. On day 2, the rats in each group were sacrificed under anesthesia. Results: Histological evaluation showed CYP administration induced severe IC with marked edema, hemorrhage and inflammation in CYP and CYP+PRP groups, but that PRP did not suppress these histopathological changes. Conclusion: PRP did not suppress the histopathological changes in rats that had IC due to cyclophosphamide injection.Öğe SURGICAL TREATMENT IN WOMEN WITH ANORGASMIA: OUR INITIAL EXPERIENCE RESULTS(Wiley-Blackwell, 2014) Karatas, O. F.; Badem, H.; Incebay, I. B.; Cavis, M.; Cimentepe, E.; Yildirim, M. E.[Abstract Not Available]Öğe The association between plasma visfatin levels and ED(Nature Publishing Group, 2015) Karatas, O. F.; Yildirim, M. E.; Celik, H. T.; Badem, H.; Cavis, M.; Cimentepe, E.Visfatin was initially proposed as a clinical marker of atherosclerosis, endothelial dysfunction and vascular damage, with a potential prognostic value. It has been shown that endothelial dysfunction has an important role in ED. We aimed to determine the levels of visfatin in ED patients and characterize the relationship between visfatin levels and ED. This case-control study was conducted between October 2010 and August 2012, and 41 severe ED patients (group 1) and 36 healthy controls (group 2) were involved. Fasting visfatin level was measured with enzyme-linked immunosorbent assay method. The groups were compared in terms of some clinical (height, weight and body mass index) and biochemical parameters (glucose, triglycerides, cholesterol, low-density lipoprotein and high-density lipoprotein). No statistically significant difference in the visfatin levels was found between the patients and the controls (17, 5 +/- 14.4, 14, 9 +/- 7 and 9, respectively, P=0.399). No difference in the other clinical and biochemical parameters was observed between the two groups. No significant difference in the serum visfatin levels of ED patients compared with healthy patients was noticed. Further studies are needed to confirm the effect of visfatin on cardiometabolic diseases and ED, indeed.Öğe THE PREDICTIVE EFFECT OF NEUTROPHIL/LYMPHOCYTE RATIO ON THE SEVERITY OF ERECTILE DYSFUNCTION(Wiley-Blackwell, 2014) Yildirim, M. E.; Badem, H.; Cavis, M.; Karatas, O. F.; Cimentepe, E.[Abstract Not Available]
